Biotech Investment Forum, featuring Adagene Founder Peter Luo, Suzhou Delegates and Hanhai Investment.
CABS E-Club is hosting a biotech investment forum together with Hanhai Investment, and our guests are successful serial entrepreneur Peter Luo and Suzhou Delegates.
Hanhai Investment established its first high-tech Silicon Valley incubator - Hanhai Z-Park in 2012. Due to the success of Hanhai Z-Park, Hanhai Investment will continue its success in the Silicon Valley by establishing two more incubators by 2017; focusing on BioPharmaceutical, Clean Tech and New Materials.
Hanhai is an annual sponsor to CABS, and all attendees can get
- free office spaces for at least 3 months,
- 6 free Startup University classes and
- pitching opportunities to Hanhai zPark Venture.
Time:12:30pm, January 13, 2013
Venue: Hanhai Investment Inc,
SIlicon Valley Industry Park
97 E Brokaw, San Jose 95112
The tentative agenda:
2:00- 3:00pm: Hanhai Investment Information Session: Hanhai president and Hanhai portfolio company representatives
3:00-4:00pm: Q&A and networking
PKU Entrepreneur club members are welcome to join the event for free as well.
E-club Open Enrollment 2013
Membership Fee: $50/year
Free admission to E-Club workshops
Invitation to member-only networking luncheons
Access to member-only online resources
Dr. Peter (Peizhi) Luo is the founder and Chief Executive Officer of Adagene, an emerging biopharmaceutical company focused on novel antibody technology and product pipeline development. He is a serial entrepreneur passionate about innovative technology and biopharmaceutical product development. To his work, he applies a broad multi-disciplinary approach that combines ideas and methods of experimental and computational biology, chemistry, and physics.
Previously, Peter was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. He was responsible for developing antibody generation and engineering technology as the discovery engine for Merck novel biologics. Prior to the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. He played a crucial role in building the Abmaxis management and scientific team and in shaping its technology and business strategies. Before his work at Abmaxis, Dr. Luo was the first lead scientist at Xencor specializing in computational protein design and protein laboratory.
Dr. Luo completed his postdoctoral research in protein folding at Stanford University. He received his Ph.D. in Chemistry from The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.